Molecular Markers in Diagnosis and Therapy of Lung Cancer.
スポンサーリンク
概要
- 論文の詳細を見る
Cancer is regarded as an "acquired multigene disease". Hence, diagnosis and treatment of cancer based on molecular pathogenesis are potentially superior to conventional methods. There have been many reports concerning the significance of molecular markers in the diagnosis and therapy of lung cancer over the last 10 years. Those include identification of people more susceptible to lung cancer by SNP analysis, early diagnosis or molecular staging based on highly sensitive PCR technology, or molecular markers as prognosticators or predictors of chemosensitivity. However, there is no evidence, established by good quality clinical trials, of the superiority of molecular-based approaches to conventional ones for the better outcome of patients with lung cancer. Recently, owing to the Human Genome Project and the advent of DNA chip technology, it has become possible to perform comprehensive analysis of cancer by expression profiling. It is now the focus of interest of many investigators to accurately predict patient prognosis or sensitivity to treatment, although it has been difficult to do so by analysis of single or limited numbers of gene (s). Iressa is a newly introduced molecular-targeted drug for lung cancer and it specifically inhibits EGFR tyrosine kinase. Although it is not possible to predict which patients would benefit from Iressa treatment, it will soon be possible in the near future. For the future development of this field, it is important to accumulate specimens of good quality from patients who are treated under the same protocol as well as to develop more sophisticated methodology.
- 特定非営利活動法人 日本肺癌学会の論文
特定非営利活動法人 日本肺癌学会 | 論文
- 診療科からみた新しいTNM病期分類（UICC-7）の問題点と課題?画像診断からみた問題点と課題?
- 新潟県における肺がんの解析
- 慢性血栓塞栓性肺高血圧症合併肺腺癌に対する左上葉切除術を施行した1例
- 肺がん検診における判定基準の改訂（2）：B，C，D判定に関して
- 片側性多発脳神経障害（Garcin症候群）を契機に発見され，化学療法により神経症状の改善を得た小細胞肺癌の1例